New Crown Outbreak: 30.33 million! Lilly and Amjin strong joint: production and antibody supply worldwide, prevention and treatment COVID-19!

September 18, 2020 / / -- At present, the outbreak of new crown pneumonia abroad is still spreading rapidly.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 0900 hours on September 18, 2020, there were more than 30.33 million confirmed cases and more than 950,000 deaths worldwide.
currently, several pharmaceutical giants are developing antibody therapies to prevent and/or treat COVID-19, including AstraZeneza's antibody cocktail therapy AZD7442, Roche/Regenerative Antibody Cocktail Therapy REGN-COV2, Lilly Media and Antibody LY-CoV555.
recently, Eli Lilly and Amgen announced a global antibody manufacturing partnership to significantly increase Lilly's global supply of potential COVID-19 antibody therapies.
, Lilly is currently studying several potentially meso-antibodies for the prevention and/or treatment of COVID-19, 2007, 2015, 2015, 2015, available as monotherapy, or as combination therapies.
the partnership, if one or more of Lilly's antibody therapies are successful in clinical trials and regulatory approval, the two companies will be able to rapidly scale up production to serve more patients around the world.
"Based on our initial clinical studies, we believe that virus-in-the-virus antibodies, including LY-CoV-555, may play an important role in the fight against COVID-19," said Dr. Daniel Skovronsky, chief scientific officer of Lilly and president of Lilly Research Laboratory.
the next step in improving the production capacity of our medium-to-antibodies through our partnership with Amn, we hope that even next year we will be able to produce millions of doses of antibodies together. Esteban Santos, executive vice president of operations and research and development at
, said, "We were impressed by Lilly's data, particularly the decline in hospitalization rates, and looked forward to the potential of these medium antibodies as a treatment for COVID-19.
we are proud to work with Lilly to leverage our deep technical expertise in antibody development, especially our ability to scale up and produce complex biologics.
is another example of how our industry is working closely together to fight this devastating disease and help patients around the world access new treatments.
"LY-CoV555 is a powerful, neutral IgG1 monoclonal antibody against SARS-CoV-2 echithrin designed to neutralate viruses, prevent viruses from attaching to and entering human cells, and potentially prevent and treat COVID-19.
LY-CoV555 is derived from Lilly's collaboration with AbCellera in developing antibody therapies to prevent and treat COVID-19.
after Ab Cellera was discovered and tested by scientists at the NIAID Vaccine Research Center, Lilly scientists quickly developed the antibody, which was identified from a blood sample taken from the first COVID-19 rehabilitation patients in the United States.
, Lilly has successfully completed a Phase I study (NCT04411628) for COVID-19 inpatients and is conducting long-term follow-up.
BLAZE-1, a Phase 2 study (NCT04427501) for patients recently diagnosed with COVID-19 in outpatient clinics.
current trends, the number of participants is expected to be completed in September, with preliminary data to be released shortly thereafter and full data to be released in the fourth quarter.
LY-CoV555 has good tolerance at all trial doses and no drug-related adverse events (SAEs) have been observed to date.
In early August, Lilly announced the launch of phase III BLAZE-2 trials to assess residents and staff of LY-CoV555 in long-term care facilities (professional care facilities, usually nursing homes and assisted living communities) in the United States to prevent new coronavirus (SARS-CoV-2) infections and new coronavirus pneumonia (COVID-19).
SARS-CoV-2 is the virus that causes COVID-19.
sars-CoV-2 spread rapidly among residents of long-term care facilities, coupled with high mortality rates among older people, there is an urgent need for treatment to prevent COVID-19 in this vulnerable population.
this is the first COVID-19 study of its kind, and will bring in 2,400 residents and staff of long-term care facilities, using customized mobile research units for on-site research.
, more than 40 percent of coronavirus deaths in the United States are linked to long-term care facilities, and treatment strategies are urgently needed to prevent COVID-19 in this vulnerable population.
() Original origin: Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies.